trending Market Intelligence /marketintelligence/en/news-insights/trending/X5GQu1xa06ZabJg4bBV71g2 content esgSubNav
In This List

SK Capital acquires Perrigo's active pharmaceutical ingredients business

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


SK Capital acquires Perrigo's active pharmaceutical ingredients business

Perrigo Co. plc's active pharmaceutical ingredients business was renamed to Wavelength Pharmaceuticals after U.S. private investment firm SK Capital completed the acquisition.

Wavelength produces generic active pharmaceutical ingredients, with primary operations in Israel and supporting functions in the U.S. and India.

Apollo Global Management and its affiliates along with MidCap Financial provided debt financing for the transaction. RBC Capital Markets LLC and Rothschild acted as SK Capital's joint advisers.